Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy

被引:10
作者
Araki, Kazuhiro
Igarashi, Tatsuo
Tobe, Toyofusa
Mizoguchi, Kenichi
Suzuki, Hiroyoshi
Furuya, Yuzo
Ichikawa, Tomohiko
Nakatsu, Hiro-Omi
Ito, Haruo
机构
[1] Chiba Univ, Grad Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan
[2] Chiba Univ, Res Ctr Frontier Med Engn, Chiba, Japan
[3] Asahi Gen Hosp, Dept Urol, Chiba, Japan
关键词
D O I
10.1016/j.urology.2006.08.1071
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives. To identify the prognostic factors in patients with recurrent renal cell carcinoma after nephrectomy, various factors were assessed, with special attention to serum immunosuppressive acidic protein (IAP) and its doubling time. Methods. Age, sex, stage, grade, histopathologic type, primary tumor size, site and number of metastatic organs, time to recurrence, IAP levels before nephrectomy and at the diagnosis of recurrence, and IAP doubling time just before recurrence were analyzed in 125 patients with recurrent renal cell carcinoma after nephrectomy. Results. Univariate analysis identified stage, grade, histopathologic type, primary tumor size, time to recurrence, IAP level at the diagnosis of recurrence, and IAP doubling time as significant prognostic factors. After exclusion of confounding factors, multivariate analysis showed that IAP doubling time was the most potent independent prognostic factor. Patient survival rates dichotomized according to IAP doubling time were compared at 100-day intervals from 100 to 700 days and 1000 and 2000 days. The maximal difference in survival rate was found when the cutoff level in the IAP doubling time was set at 200 days. Conclusions. The results of our study have shown that the IAP doubling time is a potent prognostic factor in patients with recurrent renal cell carcinoma. Periodic checkups with serum IAP level monitoring are recommended to predict prognosis after recurrence.
引用
收藏
页码:1178 / 1182
页数:5
相关论文
共 21 条
[1]
Aaltomaa S, 1997, EUR UROL, V31, P350
[2]
Metastatic renal carcinoma comprehensive prognostic system [J].
Atzpodien, J ;
Royston, P ;
Wandert, T ;
Reitz, M .
BRITISH JOURNAL OF CANCER, 2003, 88 (03) :348-353
[3]
C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy [J].
Casamassima, A ;
Picciariello, M ;
Quaranta, M ;
Berardino, R ;
Ranieri, C ;
Paradiso, A ;
Lorusso, V ;
Guida, M .
JOURNAL OF UROLOGY, 2005, 173 (01) :52-55
[4]
Citterio G, 1997, EUR UROL, V31, P286
[5]
ELSON PJ, 1988, CANCER RES, V48, P7310
[6]
IGARASHI T, 1991, EUR UROL, V19, P332
[7]
Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma [J].
Igarashi, T ;
Tobe, T ;
Kuramochi, H ;
Akakura, K ;
Ichikawa, T ;
Hamano, S ;
Suzuki, N ;
Furuya, Y ;
Ito, H .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (01) :13-17
[8]
IGARASHI T, 1995, JPN J TUMOR MARKER R, V10, P25
[9]
IGARASHI T, 1993, JPN J UROL, V84, P884
[10]
Interleukin-1 increases expression of the LYT-10 (NFκB2) proto-oncogene transcription factor in renal cell carcinoma lines [J].
Kurzrock, R ;
Estrov, Z ;
Ku, S ;
Leonard, M ;
Talpaz, M .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (03) :261-268